Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized cancer treatment.
• Current CAR-T therapies face limitations due to challenges in controlling pharmacokinetics and pharmacodynamics.
• Severe medical complications necessitate methods to regulate CAR-T cell activity in vivo.

Purpose of the Study:

• To propose and evaluate the barnase-barstar system for controlling the cytotoxic antitumor activity of CAR-T cells.
• To develop a controllable CAR-T therapy by managing its in vivo activity.

Main Methods:

• Utilized the barnase-barstar system for inducible regulation of CAR-T cell activity.
• Developed barstar-modified CAR-T cells for controlled interaction with barnase-based molecules.
• Fused barnase with designed ankyrin repeat proteins (DARPins) targeting HER2 (human epidermal growth factor receptor 2).

Main Results:

• Demonstrated pronounced regulatory effects on CAR-T cell targeting activity.
• Successfully managed the activity of CAR-T cells using the barnase-barstar system.
• Showcased the potential for enhanced safety and efficacy in CAR-T therapy.

Conclusions:

• The barnase-barstar system offers a viable strategy for controlling CAR-T cell activity.
• This approach addresses critical limitations in current CAR-T therapies, improving safety profiles.
• Further development of this system could lead to more effective and safer cancer immunotherapies.